Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic

Completed

Conditions studied: Obsessive Compulsive Disorder, Major Depressive Disorder, Anxiety

In brief

The purpose of this study is to examine the feasibility, acceptability, and utility of pharmacogenomic (PGX) testing (specifically for the cytochrome P450 2D6 and 2C19 genes) prior to initiating treatment with an antidepressant (AD) among children and adolescents in the University of Florida Child Psychiatry clinics.

Key facts

Study ID

NCT02855580

Run by

University of Florida

People needed

71

Starts

2016-09-01

Expected to finish

2017-07-06

Last updated by the study team

2019-06-10

Who can join

Age: 8 and older, up to 20. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female age 8 to 20 years old
• Have been diagnosed with and receiving treatment for mood disorder, anxiety, or obsessive compulsive disorder
• Receiving treatment at UF child psychiatry clinic

You may not qualify if…

• Children with a primary diagnosis of autism
• High risk for suicide
• Children determined by UF psychiatrist to be too ill to tolerate waiting two weeks to begin medication treatment

Where it is running

• Child Psychiatry Clinic at University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.